| Literature DB >> 35707043 |
Luqing He1, Chenyu Ma2, Shuiqi Cai3, Ruolin Hou4, Hongfeng Xu5, Jianqiang Liu6, Xin Liu4, Qun Huang3.
Abstract
Through the network pharmacology thought, the action target of the active ingredients of Drynariae Rhizoma was predicted, and the mapping was combined with the related targets of ONFH, and the key nodes of interaction were identified for enrichment analysis, so as to comprehensively explore the pharmacological mechanism of Drynariae Rhizoma against ONFH. The main active ingredients of Drynariae Rhizoma were screened based on pharmacokinetic characteristics in pharmacokinetic database and analysis platform of TCM system (TCMSP). We used the organic small molecule bioactivity database (PubChem) and Swiss target prediction database to predict related targets based on 2D or 3D structural similarity and then mined the known ONFH therapeutic targets through the Human Mendelian Genetic Database (OMIM) and Pubmed texts. Combined with the predicted targets, String database was imported to construct the OP target interaction network diagram of bone fracture therapy. CytoNCA software was used to topology the key nodes of interaction according to relevant node parameters, and String was imported again to construct the protein interaction network diagram. Finally, biological functions and metabolic pathways of key nodes were analyzed through DAVID database. It was revealed that Drynariae Rhizoma may regulate stem cells, osteoblasts, osteoclasts, and immune cells through multiple pathways, including proliferation, differentiation, immunity, and oxidative stress.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35707043 PMCID: PMC9192254 DOI: 10.1155/2022/3631722
Source DB: PubMed Journal: Comput Math Methods Med ISSN: 1748-670X Impact factor: 2.809
Potential active compounds in Drynariae Rhizoma with OB and DL parameters.
| mol ID | Compound name | Structural information | OB% | DL |
|---|---|---|---|---|
| 5280445 | Luteolin | 2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromen-4-one | 36.16 | 0.25 |
| 222284 | Beta-sitosterol | 24-ethylcholest-5-en-3 beta-ol | 36.91 | 0.75 |
| 101729 | Cyclolaudenol | 15-(5,6-dimethylhept-6-en-2-yl)-7,7,12,16-tetramethyl-6-pentacyclo | 39.05 | 0.79 |
| 91692436 | 22-Stigmasten-3-one | 17-[(E,2R,5R)-5-ethyl-6-methylhept-3-en-2-yl]-10,13-dimethyl-tetradecahydrocyclopenta | 39.25 | 0.76 |
| 12305360 | Cycloartenone | 7,7,12,16-tetramethyl-15-[(2R)-6-methylhept-5-en-2-yl]pentacyclo | 40.57 | 0.79 |
| 14309735 | Xanthogalenol | [2,6-dihydroxy-4-methoxy-3-(3-methylbut-2-enyl)phenyl]-3-(4-hydroxyphenyl)prop | 41.08 | 0.32 |
| 373261 | Eriodyctiol (flavanone) | (2R)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-2,3-dihydrochromen-4-one | 41.35 | 0.24 |
| 6427354 | Cyclolaudenol acetate | 15-(5,6-dimethylhept-6-en-2-yl)-7,7,12,16-tetramethyl-6-pentacyclo[9,8.012,16] acetate | 41.66 | 0.79 |
| 5280863 | Kaempferol | 3,5,7-trihydroxy-2-(4-hydroxyphenyl)chromen-4-one | 41.88 | 0.24 |
| 667495 | (2R)-5,7-dihydroxy-2-(4-hydroxyphenyl)chroman-4-one | (2R)-5,7-dihydroxy-2-(4-hydroxyphenyl)chroman-4-one | 42.36 | 0.21 |
| 5280794 | Stigmasterol | 10,13-dimethyl-14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol | 43.83 | 0.76 |
| 5281220 | Aureusidin | [(3,4-dihydroxyphenyl)methylidene]-4,6-dihydroxy-1-benzofuran-3-one | 53.42 | 0.24 |
| 9064 | (+)-catechin | (2R,3S)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-2H-chromene-3,5,7-triol | 54.83 | 0.24 |
| 932 | Naringenin | 5,7-dihydroxy-2-(4-hydroxyphenyl)-2,3-dihydrochromen-4-one | 59.29 | 0.21 |
| 54711004 | Digallate | 4-(5-carboxy-2,3-dihydroxyphenoxy)carbonyl-2,6-dihydroxyphenolate | 61.85 | 0.26 |
| 44257070 | Davallioside A_qt | 5,7-dihydroxy-3-[(2R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydro-2H-chromen-8-yl]pyrrolidin-2-one | 62.65 | 0.51 |
| 10411827 | Marioside_qt | 3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxane-2,3,4,5-tetrol | 70.79 | 0.19 |
| 440735 | Eriodictyol | (2S)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-2,3-dihydrochromen-4-one | 71.79 | 0.24 |
Figure 1The network of “ Drynariae Rhizoma – active compounds – potential targets”.
Figure 2Network of 16 active compounds of Rhizoma Drynariae and 118 putative targets.
Figure 3Network of 97 key nodes based on their direct interactions.
Figure 4GO and KEGG enrichment analysis of key targets.
Active ingredients and key targets of Drynariae Rhizoma in treating ONFH.
| No. | Active ingredients | Key targets |
|---|---|---|
| 1 | Luteolin | MMP1, MMP2, and MMP13 |
| 2 | Beta-sitosterol | AR, CYP19A1, CYP17A1, LDLR, ESR1, and ESR2 |
| 3 | Cyclolaudenol | LDLR, HSD11B1, and UGT2B17 |
| 4 | 22-Stigmasten-3-one | TRPV1, TRPV4, and CYP19A1 |
| 5 | Cycloartenone | CYP19A1, TRPV1, TRPV4, CYP17A1, and NR3C1 |
| 6 | Xanthogalenol | CYP19A1 and NOS3 |
| 7 | Eriodyctiol (flavanone) | CYP1B1, CYP1A1, CYP19A1, MMP1, and MMP13 |
| 8 | Kaempferol | ABCB1, HSD17B1, ALOX15, ALOX12, and CYP1B1 |
| 9 | Stigmasterol | AR, CYP19A1, LDLR, CYP17A1, ESR1, and ESR2 |
| 10 | Aureusidin | ERBB2 |
| 11 | (+)-catechin | CA2 |
| 12 | Naringenin | CYP19A1, HSD17B1, CYP1B1, CYP1A1, and ESR1 |
| 13 | Digallate | CA2 |
| 14 | Davallioside A_qt | MMP2 and CA2 |
| 15 | Marioside_qt | STAT1 and MMP2 |
| 16 | Eriodictyol | CYP1B1, CYP1A1, CYP19A1, MMP1 and MMP13 |